Work

A 2-Part Phase I Study in Patients with Solid or Hematologic Malignancies: Dose Proportionality of Subcutaneous (SC) Azacitidine (AZA) and Pharmacokinetics of SC AZA in Patients with Severe Renal Impairment,

Year: 2011

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v118.21.3480.3480

Authors: Eric Laille, Alain C. Mita, Sanjay Goel, Nashat Y. Gabrail, Joseph Schwarz, CL Beach

Institutions: Celgene (United States), The University of Texas at San Antonio Health Science Center, Montefiore Einstein Comprehensive Cancer Center, Gabrail Cancer Center

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2522061626

FWCI:

Cites:

Cited by:

Related to: 10